Cargando…
Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
Parkinson’s disease (PD) is the second leading neurodegenerative disease that is characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been considered a mainstay for the management of PD; however, its prolonged treatment is often associated with abnormal involuntary moveme...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021725/ https://www.ncbi.nlm.nih.gov/pubmed/35462934 http://dx.doi.org/10.3389/fphar.2022.805388 |
_version_ | 1784689896656470016 |
---|---|
author | Bandopadhyay, Ritam Mishra, Nainshi Rana, Ruhi Kaur, Gagandeep Ghoneim, Mohammed M. Alshehri, Sultan Mustafa, Gulam Ahmad, Javed Alhakamy, Nabil. A. Mishra, Awanish |
author_facet | Bandopadhyay, Ritam Mishra, Nainshi Rana, Ruhi Kaur, Gagandeep Ghoneim, Mohammed M. Alshehri, Sultan Mustafa, Gulam Ahmad, Javed Alhakamy, Nabil. A. Mishra, Awanish |
author_sort | Bandopadhyay, Ritam |
collection | PubMed |
description | Parkinson’s disease (PD) is the second leading neurodegenerative disease that is characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been considered a mainstay for the management of PD; however, its prolonged treatment is often associated with abnormal involuntary movements and results in L-DOPA-induced dyskinesia (LID). Although LID is encountered after chronic administration of L-DOPA, the appearance of dyskinesia after weeks or months of the L-DOPA treatment has complicated our understanding of its pathogenesis. Pathophysiology of LID is mainly associated with alteration of direct and indirect pathways of the cortico-basal ganglia-thalamic loop, which regulates normal fine motor movements. Hypersensitivity of dopamine receptors has been involved in the development of LID; moreover, these symptoms are worsened by concurrent non-dopaminergic innervations including glutamatergic, serotonergic, and peptidergic neurotransmission. The present study is focused on discussing the recent updates in molecular mechanisms and therapeutic approaches for the effective management of LID in PD patients. |
format | Online Article Text |
id | pubmed-9021725 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90217252022-04-22 Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence Bandopadhyay, Ritam Mishra, Nainshi Rana, Ruhi Kaur, Gagandeep Ghoneim, Mohammed M. Alshehri, Sultan Mustafa, Gulam Ahmad, Javed Alhakamy, Nabil. A. Mishra, Awanish Front Pharmacol Pharmacology Parkinson’s disease (PD) is the second leading neurodegenerative disease that is characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been considered a mainstay for the management of PD; however, its prolonged treatment is often associated with abnormal involuntary movements and results in L-DOPA-induced dyskinesia (LID). Although LID is encountered after chronic administration of L-DOPA, the appearance of dyskinesia after weeks or months of the L-DOPA treatment has complicated our understanding of its pathogenesis. Pathophysiology of LID is mainly associated with alteration of direct and indirect pathways of the cortico-basal ganglia-thalamic loop, which regulates normal fine motor movements. Hypersensitivity of dopamine receptors has been involved in the development of LID; moreover, these symptoms are worsened by concurrent non-dopaminergic innervations including glutamatergic, serotonergic, and peptidergic neurotransmission. The present study is focused on discussing the recent updates in molecular mechanisms and therapeutic approaches for the effective management of LID in PD patients. Frontiers Media S.A. 2022-04-07 /pmc/articles/PMC9021725/ /pubmed/35462934 http://dx.doi.org/10.3389/fphar.2022.805388 Text en Copyright © 2022 Bandopadhyay, Mishra, Rana, Kaur, Ghoneim, Alshehri, Mustafa, Ahmad, Alhakamy and Mishra. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Bandopadhyay, Ritam Mishra, Nainshi Rana, Ruhi Kaur, Gagandeep Ghoneim, Mohammed M. Alshehri, Sultan Mustafa, Gulam Ahmad, Javed Alhakamy, Nabil. A. Mishra, Awanish Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence |
title | Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence |
title_full | Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence |
title_fullStr | Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence |
title_full_unstemmed | Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence |
title_short | Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence |
title_sort | molecular mechanisms and therapeutic strategies for levodopa-induced dyskinesia in parkinson’s disease: a perspective through preclinical and clinical evidence |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021725/ https://www.ncbi.nlm.nih.gov/pubmed/35462934 http://dx.doi.org/10.3389/fphar.2022.805388 |
work_keys_str_mv | AT bandopadhyayritam molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence AT mishranainshi molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence AT ranaruhi molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence AT kaurgagandeep molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence AT ghoneimmohammedm molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence AT alshehrisultan molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence AT mustafagulam molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence AT ahmadjaved molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence AT alhakamynabila molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence AT mishraawanish molecularmechanismsandtherapeuticstrategiesforlevodopainduceddyskinesiainparkinsonsdiseaseaperspectivethroughpreclinicalandclinicalevidence |